CA
RYTM icon

Continuum Advisory’s Rhythm Pharmaceuticals RYTM Stock Holding History

Continuum Advisory’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-13
Closed -$777 – 1946
2024
Q3 		$777 Buy
+13
New +$623 ﹤0.01% 1689

Other funds holding RYTM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Continuum Advisory's RYTM Position: Q4 2024 in Review

Continuum Advisory sold out of Rhythm Pharmaceuticals (RYTM) in Q4 2024, closing a stake of 13 shares — an estimated $777 sold.

Continuum Advisory first reported a position in RYTM in Q3 2024 and held it in 1 quarter. The position peaked at $777 in Q3 2024. 203 funds tracked by Wall St. Rank hold RYTM as of Q4 2024.

  • Continuum Advisory reported no remaining Rhythm Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Continuum Advisory sold 13 Rhythm Pharmaceuticals shares in Q4 2024, an estimated $777.
  • Continuum Advisory first reported a position in Rhythm Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Continuum Advisory's Rhythm Pharmaceuticals position peaked at $777 in Q3 2024.
  • 203 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q4 2024.

Based on Continuum Advisory's 13F filing for Q4 2024, filed 18 Feb 2025.